Aryl substituted tetrazole derivatives, and application thereof in therapeutics

Claim 1

Derivatives of formula: ##STR35## in which the chain ##STR36## represents 1) either the chain of structure: ##STR37## where A is: a) a vinyl group or a (CH 2 ) n --Z 1 group in which Z 1 represents a CN, methoxy or ethoxy group and n is an integer from 1 to 6, in which case Ar takes on the value Ar 1 which represents: a phenyl nucleus substituted by benzyloxy group of formula: ##STR38## where R 1 represents a hydrogen atom, one or two halogen atoms or a CN, NO 2 , NH 2 , CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy or C 2 -C 4 acylamino group; or b) a group of formula (CH 2 ) m --Z 2 in which Z 2 represents an OH group, a halogen atom, an NH 2 , an NH 2 group substituted by one or two C 1 -C 4 alkyl groups, a C 2 -C 4 acylamino group or a phthalimido group and m is an integer from 2 to 6, in which case Ar takes on the value Ar 2 which represents: a phenyl nucleus substituted by a benzyloxy group of formula ##STR39## where R 1 has the same meaning as above; as well as the pharmaceutically acceptable acid addition salts of these derivatives (I) having a salifiable group, with the exclusion of 5-phenyl 2-tetrazole butyronitrile and 5-phenyl 2-tetrazole valeronitrile.

Claim 25

A method of treating a patient to inhibit type B monoamine oxidase which comprises administering to the patient a therapeutically effective amount of a compound of formula (I) ##STR56## in which the chain ##STR57## 1) either the chain of structure ##STR58## where A is a) a vinyl group or a (CH 2 ) n --Z 1 group in which Z 1 represents a CN, methoxy or ethoxy group and n is an integer from 1 to 6, in which case Ar takes on the value Ar 1 which represents a phenyl nucleus; a phenyl nucleus substituted by one or two halogen atoms or an NO 2 , methyl, ethyl, methoxy, ethoxy, phenyl or benzyloxy group of formula ##STR59## where R 1 represents a hydrogen atom, one or two halogen atoms or a CN, NO 2 , CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy or C 2 -C 4 acylamino group; or b) a group of formula (CH 2 ) m --Z 2 in which Z 2 represents an OH group, a halogen atom, an NH 2 , an NH 2 group substituted by one or two C 1 -C 4 alkyl groups, a C 2 -C 4 acylamino group or a phthalimido group and m is an integer from 2 to 6, in which case Ar takes on the value Ar 2 which represents a phenyl nucleus substituted by a C 1 -C 4 alkoxy group or a benzyloxy group of formula ##STR60## where R 1 has the same meaning as above; or a pharmaceutically acceptable salt thereof with exclusion of 5-phenyl 2-tetrazole butyronitrile and 5-phenyl 2-tetrazole valeronitrile.

Claim 26

A method of treating a patient to inhibit type B monoamine oxidase which comprises administering to the patient a therapeutically effective amount of a compound of formula (I) ##STR56## in which the chain ##STR57## 1) either the chain of structure ##STR58## where A is a) a vinyl group or a (CH 2 ) n --Z 1 group in which Z 1 represents a CN, methoxy or ethoxy group and n is an integer from 1 to 6, in which case Ar takes on the value Ar 1 which represents a phenyl nucleus; a phenyl nucleus substituted by one or two halogen atoms or an NO 2 , methyl, ethyl, methoxy, ethoxy, phenyl or benzyloxy group of formula ##STR59## where R 1 represents a hydrogen atom, one or two halogen atoms or a CN, NO 2 , CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy or C 2 -C 4 acylamino group; or b) a group of formula (CH 2 ) m --Z 2 in which Z 2 represents an OH group, a halogen atom, an NH 2 , an NH 2 group substituted by one or two C 1 -C 4 alkyl groups, a C 2 -C 4 acylamino group or a phthalimido group and m is an integer from 2 to 6, in which case Ar takes on the value Ar 2 which represents a phenyl nucleus substituted by a C 1 -C 4 alkoxy group or a benzyloxy group of formula ##STR60## where R 1 has the same meaning as above; or a pharmaceutically acceptable salt thereof with exclusion of 5-phenyl 2-tetrazole butyronitrile and 5-phenyl 2-tetrazole valeronitrile.